{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:22:54Z","timestamp":1793712174423,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C2008235"],"award-info":[{"award-number":["2021R1A2C2008235"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05587-0","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:19:18Z","timestamp":1762424358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-throughput screening and meta-analysis for lead compounds in antimalarial drug discovery"],"prefix":"10.1186","volume":"24","author":[{"given":"Nguyen","family":"Van Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Won","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyet-Kha","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Sy","family":"Thau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi-Thanh Hang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bazgha","family":"Sanaullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ch","family":"Venkataramaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hun","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Joo","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hwan","family":"No","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Taek","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"5587_CR1","unstructured":"WHO. World Malaria Report 2024. Geneva, World Health Organization, 2024."},{"key":"5587_CR2","unstructured":"WHO. Strategy to respond to antimalarial drug resistance in Africa. Geneva, World Health Organization, 2022."},{"key":"5587_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s42003-022-03215-0","volume":"5","author":"L Zhu","year":"2022","unstructured":"Zhu L, van der Pluijm RW, Kucharski M, Nayak S, Tripathi J, White NJ, et al. Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Commun Biol. 2022;5:274.","journal-title":"Commun Biol"},{"key":"5587_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000999","volume":"3","author":"CO Lucy","year":"2018","unstructured":"Lucy CO, Lisa Malene R, Lene Sand\u00f8 E, Vito B, Donal B, Oliver JW, et al. Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa. BMJ Glob Health. 2018;3:e000999.","journal-title":"BMJ Glob Health"},{"issue":"9","key":"5587_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19(9):952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"5587_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cbpa.2007.05.038","volume":"11","author":"MH Gelb","year":"2007","unstructured":"Gelb MH. Drug discovery for malaria: a very challenging and timely endeavor. Curr Opin Chem Biol. 2007;11:440\u20135.","journal-title":"Curr Opin Chem Biol"},{"key":"5587_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fphar.2020.00770","volume":"11","author":"IV Hinkson","year":"2020","unstructured":"Hinkson IV, Madej B, Stahlberg EA. Accelerating therapeutics for opportunities in medicine: a paradigm shift in drug discovery. Front Pharmacol. 2020;11:770.","journal-title":"Front Pharmacol"},{"key":"5587_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nature09107","volume":"465","author":"FJ Gamo","year":"2010","unstructured":"Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010;465:305\u201310.","journal-title":"Nature"},{"key":"5587_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature09099","volume":"465","author":"WA Guiguemde","year":"2010","unstructured":"Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, et al. Chemical genetics of Plasmodium falciparum. Nature. 2010;465:311\u20135.","journal-title":"Nature"},{"key":"5587_CR10","doi-asserted-by":"publisher","first-page":"9059","DOI":"10.1073\/pnas.0802982105","volume":"105","author":"D Plouffe","year":"2008","unstructured":"Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5587_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.pt.2016.04.014","volume":"32","author":"ML Hovlid","year":"2016","unstructured":"Hovlid ML, Winzeler EA. Phenotypic screens in antimalarial drug discovery. Trends Parasitol. 2016;32:697\u2013707.","journal-title":"Trends Parasitol"},{"key":"5587_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00754","volume":"8","author":"S Sinha","year":"2017","unstructured":"Sinha S, Sarma P, Sehgal R, Medhi B. Development in assay methods for in vitro antimalarial drug efficacy testing: a systematic review. Front Pharmacol. 2017;8:754.","journal-title":"Front Pharmacol"},{"key":"5587_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2012.236","volume":"93","author":"DC Swinney","year":"2013","unstructured":"Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther. 2013;93:299\u2013301.","journal-title":"Clin Pharmacol Ther"},{"key":"5587_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1128\/AAC.01144-06","volume":"51","author":"ML Baniecki","year":"2007","unstructured":"Baniecki ML, Wirth DF, Clardy J. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother. 2007;51:716\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"5587_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep16414","volume":"5","author":"L Lucantoni","year":"2015","unstructured":"Lucantoni L, Silvestrini F, Signore M, Siciliano G, Eldering M, Dechering KJ, et al. A simple and predictive phenotypic high content imaging assay for Plasmodium falciparum mature gametocytes to identify malaria transmission blocking compounds. Sci Rep. 2015;5:16414.","journal-title":"Sci Rep"},{"key":"5587_CR16","unstructured":"Administration USFaD. The drug development Process. 2018."},{"key":"5587_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nrd2144","volume":"5","author":"S Nwaka","year":"2006","unstructured":"Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006;5:941\u201355.","journal-title":"Nat Rev Drug Discov"},{"key":"5587_CR18","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12:3049\u201362.","journal-title":"Acta Pharm Sin B"},{"key":"5587_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.1260867","volume":"347","author":"J Straimer","year":"2015","unstructured":"Straimer J, Gn\u00e4dig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347:428\u201331.","journal-title":"Science"},{"key":"5587_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0020-7519(97)00080-5","volume":"27","author":"W Trager","year":"1997","unstructured":"Trager W, Jensen JB. Continuous culture of Plasmodium falciparum: its impact on malaria research. Int J Parasitol. 1997;27:989\u20131006.","journal-title":"Int J Parasitol"},{"key":"5587_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2307\/3280287","volume":"65","author":"C Lambros","year":"1979","unstructured":"Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65:418\u201320.","journal-title":"J Parasitol"},{"key":"5587_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4269\/ajtmh.2010.09-0417","volume":"82","author":"MG Vossen","year":"2010","unstructured":"Vossen MG, Pferschy S, Chiba P, Noedl H. The SYBR green I malaria drug sensitivity assay: performance in low parasitemia samples. Am J Trop Med Hyg. 2010;82:398\u2013401.","journal-title":"Am J Trop Med Hyg"},{"key":"5587_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12936-018-2420-4","volume":"17","author":"F Muh","year":"2018","unstructured":"Muh F, Lee S-K, Hoque MR, Han J-H, Park J-H, Firdaus ER, et al. In vitro invasion inhibition assay using antibodies against Plasmodium knowlesi Duffy binding protein alpha and apical membrane antigen protein 1 in human erythrocyte-adapted P. knowlesi A1\u2013H.1 strain. Malar J. 2018;17:272.","journal-title":"Malar J"},{"key":"5587_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pst.426","volume":"10","author":"JL Sebaugh","year":"2011","unstructured":"Sebaugh JL. Guidelines for accurate EC50\/IC50 estimation. Pharm Stat. 2011;10:128\u201334.","journal-title":"Pharm Stat"},{"key":"5587_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-198510030-00001","volume":"10","author":"NJ White","year":"1985","unstructured":"White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985;10:187\u2013215.","journal-title":"Clin Pharmacokinet"},{"key":"5587_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00003088-199630040-00002","volume":"30","author":"S Krishna","year":"1996","unstructured":"Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 1996;30:263\u201399.","journal-title":"Clin Pharmacokinet"},{"key":"5587_CR27","unstructured":"WHO. Guideline for malaria. Geneva, World Health Organization, 2023."},{"key":"5587_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrd1416","volume":"3","author":"DA Fidock","year":"2004","unstructured":"Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov. 2004;3:509\u201320.","journal-title":"Nat Rev Drug Discov"},{"key":"5587_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-19","volume":"64","author":"P Sinxadi","year":"2020","unstructured":"Sinxadi P, Donini C, Johnstone H, Langdon G, Wiesner L, Allen E, et al. Safety, tolerability, pharmacokinetics, and antimalarial activity of the novel Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048 in healthy volunteers. Antimicrob Agents Chemother. 2020;64:e01896\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"5587_CR30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41598-021-04619-4","volume":"12","author":"H Bharti","year":"2022","unstructured":"Bharti H, Singal A, Saini M, Cheema PS, Raza M, Kundu S, et al. Repurposing the pathogen box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCHL3 inhibitory activity. Sci Rep. 2022;12:918.","journal-title":"Sci Rep"},{"key":"5587_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032914","volume":"24","author":"IP S\u00e6b\u00f8","year":"2023","unstructured":"S\u00e6b\u00f8 IP, Bj\u00f8r\u00e5s M, Franzyk H, Helgesen E, Booth JA. Optimization of the hemolysis assay for the assessment of cytotoxicity. Int J Mol Sci. 2023;24:2914.","journal-title":"Int J Mol Sci"},{"key":"5587_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12936-019-3060-z","volume":"18","author":"S Sinha","year":"2019","unstructured":"Sinha S, Batovska DI, Medhi B, Radotra BD, Bhalla A, Markova N, et al. In vitro anti-malarial efficacy of chalcones: cytotoxicity profile, mechanism of action, and their effect on erythrocytes. Malar J. 2019;18:421.","journal-title":"Malar J"},{"key":"5587_CR33","unstructured":"Dojindo laboratories. Cell proliferation cytotoxicity assay protocol. 2019. https:\/\/www.dojindo.com\/EUROPE\/contents\/cell-proliferation-cytotoxicity-assay-kits-selection-guide.html"},{"key":"5587_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1039\/a809656b","volume":"36","author":"H Tominaga","year":"1999","unstructured":"Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun. 1999;36:47\u201350.","journal-title":"Anal Commun"},{"key":"5587_CR35","unstructured":"ATCC. Animal cell culture guide. https:\/\/www.atcc.org\/resources\/culture-guides\/animal-cell-culture-guide"},{"key":"5587_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/9781118789568","volume-title":"A practical guide to the histology of the mouse","author":"CL Scudamore","year":"2014","unstructured":"Scudamore CL. A practical guide to the histology of the mouse. Wiley; 2014."},{"key":"5587_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4269\/ajtmh.2012.11-0302","volume":"86","author":"S Duffy","year":"2012","unstructured":"Duffy S, Avery VM. Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. Am J Trop Med Hyg. 2012;86:84\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"5587_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/infdis\/jiq024","volume":"203","author":"M Imwong","year":"2011","unstructured":"Imwong M, Russell B, Suwanarusk R, Nzila A, Leimanis ML, Sriprawat K, et al. Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax. J Infect Dis. 2011;203:207\u201310.","journal-title":"J Infect Dis"},{"key":"5587_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJM199507203330301","volume":"333","author":"P Tugwell","year":"1995","unstructured":"Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med. 1995;333:137\u201341.","journal-title":"N Engl J Med"},{"key":"5587_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-327","volume":"13","author":"C Desgrouas","year":"2014","unstructured":"Desgrouas C, Chapus C, Desplans J, Travaille C, Pascual A, Baghdikian B, et al. In vitro antiplasmodial activity of cepharanthine. Malar J. 2014;13:327.","journal-title":"Malar J"},{"key":"5587_CR41","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/571242","volume":"2011","author":"AK Haldar","year":"2011","unstructured":"Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int. 2011;2011:571242.","journal-title":"Mol Biol Int"},{"key":"5587_CR42","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1128\/AAC.00527-07","volume":"51","author":"EL Dahl","year":"2007","unstructured":"Dahl EL, Rosenthal PJ. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother. 2007;51:3485\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"5587_CR43","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/AAC.38.3.511","volume":"38","author":"S Pukrittayakamee","year":"1994","unstructured":"Pukrittayakamee S, Viravan C, Charoenlarp P, Yeamput C, Wilson RJ, White NJ. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother. 1994;38:511\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"5587_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242372","volume":"15","author":"K Kesely","year":"2020","unstructured":"Kesely K, Noomuna P, Vieth M, Hipskind P, Haldar K, Pantaleo A, et al. Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia. PLoS ONE. 2020;15:e0242372.","journal-title":"PLoS ONE"},{"key":"5587_CR45","doi-asserted-by":"publisher","first-page":"11795","DOI":"10.1038\/s41598-023-38596-7","volume":"13","author":"Q Tong","year":"2023","unstructured":"Tong Q, Yan D, Cao Y, Dong X, Abula Y, Yang H, et al. NVS-ZP7-4 inhibits hepatocellular carcinoma tumorigenesis and promotes apoptosis via PI3K\/AKT signaling. Sci Rep. 2023;13:11795.","journal-title":"Sci Rep"},{"key":"5587_CR46","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1021\/acsinfecdis.9b00455","volume":"6","author":"KA Matthews","year":"2020","unstructured":"Matthews KA, Senagbe KM, N\u00f6tzel C, Gonzales CA, Tong X, Rijo-Ferreira F, et al. Disruption of the Plasmodium falciparum life cycle through transcriptional reprogramming by inhibitors of Jumonji demethylases. ACS Infect Dis. 2020;6:1058\u201375.","journal-title":"ACS Infect Dis"},{"key":"5587_CR47","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1007\/s11686-024-00850-x","volume":"69","author":"AP Adegunloye","year":"2024","unstructured":"Adegunloye AP, Adebayo JO. Piperine enhances antimalarial activity of methyl gallate and palmatine combination. Acta Parasitol. 2024;69:1244\u201352.","journal-title":"Acta Parasitol"},{"key":"5587_CR48","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1128\/AAC.01683-15","volume":"59","author":"I Benmerzouga","year":"2015","unstructured":"Benmerzouga I, Checkley LA, Ferdig MT, Arrizabalaga G, Wek RC, Sullivan WJ Jr. Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. Antimicrob Agents Chemother. 2015;59:6939\u201345.","journal-title":"Antimicrob Agents Chemother"},{"key":"5587_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11095-020-02799-8","volume":"37","author":"S Ekins","year":"2020","unstructured":"Ekins S, Lane TR, Madrid PB. Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond. Pharm Res. 2020;37:71.","journal-title":"Pharm Res"},{"key":"5587_CR50","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.2147\/IDR.S279433","volume":"13","author":"MA Shibeshi","year":"2020","unstructured":"Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020;13:4047\u201360.","journal-title":"Infect Drug Resist"},{"key":"5587_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061812","volume":"8","author":"S Moon","year":"2013","unstructured":"Moon S, Lee S, Kim H, Freitas-Junior LH, Kang M, Ayong L, et al. An image analysis algorithm for malaria parasite stage classification and viability quantification. PLoS ONE. 2013;8:e61812.","journal-title":"PLoS ONE"},{"key":"5587_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/B978-0-12-812364-5.00006-7","volume-title":"Computational phytochemistry","author":"F Ismail","year":"2018","unstructured":"Ismail F, Nahar P, Sarker S. High-throughput screening of phytochemicals: application of computational methods. In: Sarker S, Nahar L, editors. Computational phytochemistry. Elsevier; 2018. p. 165\u201392."},{"key":"5587_CR53","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1128\/AAC.01607-06","volume":"51","author":"JD Johnson","year":"2007","unstructured":"Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother. 2007;51:1926\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"5587_CR54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4314\/eamj.v82i3.9266","volume":"82","author":"RA Odhiambo","year":"2005","unstructured":"Odhiambo RA, Odulaja A. Parasite lactate dehydrogenase assay for the determination of antimalarial drug susceptibility of Kenyan field isolates. East Afr Med J. 2005;82:118\u201322.","journal-title":"East Afr Med J"},{"key":"5587_CR55","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3390\/molecules25081980","volume":"25","author":"T-N Phan","year":"2020","unstructured":"Phan T-N, Baek K-H, Lee N, Byun SY, Shum D, No JH. In Vitro and in Vivo activity of mTOR kinase and PI3K inhibitors against Leishmania donovani and Trypanosoma brucei. Molecules. 2020;25:1980.","journal-title":"Molecules"},{"key":"5587_CR56","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/cyto.a.22885","volume":"89","author":"MLT Ang","year":"2016","unstructured":"Ang MLT, Pethe K. Contribution of high-content imaging technologies to the development of anti-infective drugs. Cytometry A. 2016;89:755\u201360.","journal-title":"Cytometry A"},{"key":"5587_CR57","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41598-019-42801-x","volume":"9","author":"M Penzo","year":"2019","unstructured":"Penzo M, De Las H-D, Mata-Cantero L, Diaz-Hernandez B, Vazquez-Mu\u00f1iz M-J, Ghidelli-Disse S, et al. High-throughput screening of the Plasmodium falciparum cGMP-dependent protein kinase identified a thiazole scaffold which kills erythrocytic and sexual stage parasites. Sci Rep. 2019;9:7005.","journal-title":"Sci Rep"},{"key":"5587_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.pt.2019.05.004","volume":"35","author":"N Aulner","year":"2019","unstructured":"Aulner N, Danckaert A, Ihm J, Shum D, Shorte SL. Next-generation phenotypic screening in early drug discovery for infectious diseases. Trends Parasitol. 2019;35:559\u201370.","journal-title":"Trends Parasitol"},{"key":"5587_CR59","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1038\/s41598-020-60221-0","volume":"10","author":"ACC de Sousa","year":"2020","unstructured":"de Sousa ACC, Combrinck JM, Maepa K, Egan TJ. Virtual screening as a tool to discover new \u03b2-haematin inhibitors with activity against malaria parasites. Sci Rep. 2020;10:3374.","journal-title":"Sci Rep"},{"key":"5587_CR60","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12936-019-3069-3","volume":"18","author":"GE Souza","year":"2019","unstructured":"Souza GE, Bueno RV, de Souza JO, Zanini CL, Cruz FC, Oliva G, et al. Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies. Malar J. 2019;18:447.","journal-title":"Malar J"},{"key":"5587_CR61","doi-asserted-by":"publisher","first-page":"8302","DOI":"10.1038\/s41467-023-44077-2","volume":"14","author":"HC Hsu","year":"2023","unstructured":"Hsu HC, Li D, Zhan W, Ye J, Liu YJ, Leung A, et al. Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors. Nat Commun. 2023;14:8302.","journal-title":"Nat Commun"},{"key":"5587_CR62","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1002\/anie.202015845","volume":"60","author":"W Zhan","year":"2021","unstructured":"Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, et al. Development of a highly selective Plasmodium falciparum proteasome inhibitor with anti-malaria activity in humanized mice. Angew Chem Int Ed Engl. 2021;60:9279\u201383.","journal-title":"Angew Chem Int Ed Engl"},{"key":"5587_CR63","doi-asserted-by":"publisher","first-page":"210","DOI":"10.7883\/yoken.JJID.2008.210","volume":"61","author":"O Dar","year":"2008","unstructured":"Dar O, Khan MS, Adagu I. The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. Jpn J Infect Dis. 2008;61:210\u20131.","journal-title":"Jpn J Infect Dis"},{"key":"5587_CR64","doi-asserted-by":"publisher","first-page":"9893","DOI":"10.1126\/science.adk9893","volume":"386","author":"MR Luth","year":"2024","unstructured":"Luth MR, Godinez-Macias KP, Chen D, Okombo J, Thathy V, Cheng X, et al. Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance. Science. 2024;386:9893.","journal-title":"Science"},{"key":"5587_CR65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/pim.12277","volume":"37","author":"SW Howland","year":"2015","unstructured":"Howland SW, Ng GX, Chia SK, R\u00e9nia L. Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria. Parasite Immunol. 2015;37:599\u2013604.","journal-title":"Parasite Immunol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05587-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:05:15Z","timestamp":1762427115000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05587-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5587"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05587-0","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}